中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
2-溴-6-甲氧基苯酚 | 6-bromoguaiacol | 28165-49-3 | C7H7BrO2 | 203.035 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
1,2,3-三溴-4,5-二甲氧基苯 | 2,3,4-tribromoveratrole | 854872-30-3 | C8H7Br3O2 | 374.854 |
—— | 3,4,5-tribromo-2-(2',4'-dibromophenoxy)anisole | 38926-88-4 | C13H7Br5O2 | 594.717 |
To report a case of changes documented by magnetic resonance imaging (MRI) of the head probably due to accumulation of metronidazole in a patient with liver dysfunction.
A 34-year-old Hispanic man with cirrhosis and hepatitis C being treated with metronidazole for Bacteroides fragilis meningitis and bacteremia developed ataxia, disorientation, and peripheral neuropathy. An MRI at the time meningitis was diagnosed was negative. After the patient received >60 g of metronidazole, an MRI revealed increased signal intensity below, behind, and lateral to the fourth ventricle. Concomitant metronidazole serum concentration was toxic at 35.1 μg/mL.
This is the second reported case of metronidazole-induced MRI changes. Metronidazole is known to accumulate in patients with liver dysfunction and can cause peripheral neuropathy and central nervous system (CNS) dysfunction; these effects may take up to two years to completely resolve.
Metronidazole dosages should be reduced in patients with liver dysfunction to prevent the accumulation of metronidazole, which can lead to CNS dysfunction and peripheral neuropathy.